recent publications
-
academic article
- Kuo, J., Bobardt, M., Chatterji, U., Mayo, P. R., Trepanier, D. J., Foster, R. T., Gallay, P., Ure, D. R. A pan-cyclophilin inhibitor, CRV431, decreases fibrosis and tumor development in chronic liver disease models Journal of Pharmacology and Experimental Therapeutics 2019 371:231-241 DOI:10.1124/jpet.119.261099 PMID:31406003 PMCID:PMC6815936
- Kuo, J., Serrano, S. S., Gronberg, A., Massoumi, R., Hansson, M. J., Gallay, P. Cyclophilin inhibitor NV556 reduces fibrosis and hepatocellular carcinoma development in mice with non-alcoholic steatohepatitis Frontiers in Pharmacology 2019 10 DOI:10.3389/fphar.2019.01129
- Serrano, S. S., Gronberg, A., Longato, L., Rombouts, K., Kuo, J., Gregory, M., Moss, S., Elmer, E., Mazza, G., Gallay, P., Pinzani, M., Hansson, M. J., et al. Evaluation of NV556, a novel cyclophilin inhibitor, as a potential antifibrotic compound for liver fibrosis Cells 2019 8 DOI:10.3390/cells8111409 PMID:31717385 PMCID:PMC6912624
- Gallay, P., Ure, D., Bobardt, M., Chatterji, U., Ou, J., Trepanier, D., Foster, R. The cyclophilin inhibitor CRV431 inhibits liver HBV DNA and HBsAg in transgenic mice PLoS One 2019 14 DOI:10.1371/journal.pone.0217433 PMID:31181107 PMCID:PMC6557616
- Bobardt, M., Kuo, J., Chatterji, U., Chanda, S., Little, S. J., Wiedemann, N., Vuagniaux, G., Gallay, P. A. The inhibitor apoptosis protein antagonist Debio 1143 Is an attractive HIV-1 latency reversal candidate PLoS One 2019 14 DOI:10.1371/journal.pone.0211716 PMID:30716099 PMCID:PMC6361451
- Gallay, P. A., Chatterji, U., Kirchhoff, A., Gandarilla, A., Pyles, R. B., Baum, M. M., Moss, J. A. Protection Efficacy of C5A Against Vaginal and Rectal HIV Challenges in Humanized Mice The Open Virology Journal 2018 12:1-13 DOI:10.2174/1874357901812010001 PMID:29541273 PMCID:PMC5842390
- de Wilde, A. H., Zevenhoven-Dobbe, J. C., Beugeling, C., Chatterji, U., de Jong, D., Gallay, P., Szuhai, K., Posthuma, C. C., Snijder, E. J. Coronaviruses and arteriviruses display striking differences in their cyclophilin A-dependence during replication in cell culture Virology 2017 517:148-156 DOI:10.1016/j.virol.2017.11.022 PMID:29249267
- Gallay, P. A., Chatterji, U., Kirchhoff, A., Gandarilla, A., Gunawardana, M., Pyles, R. B., Marzinke, M. A., Moss, J. A., Baum, M. M. Prevention of vaginal and rectal HIV transmission by antiretroviral combinations in humanized mice PLoS One 2017 12 DOI:10.1371/journal.pone.0184303 PMID:28880948 PMCID:PMC5589224
- Vidotto, A., Morais, A. T., Ribeiro, M. R., Pacca, C. C., Terzian, A. C., Gil, L.H., Mohana-Borges, R., Gallay, P., Nogueira, M. L. Systems biology reveals NS4B-cyclophilin A interaction: A new target to inhibit YFV replication Journal of Proteome Research 2017 16:1542-1555 DOI:10.1021/acs.jproteome.6b00933 PMID:28317380
- Veazey, R. S., Chatterji, U., Bobardt, M., Russell-Lodrigue, K. E., Li, J., Wang, X., Gallay, P. A. C5A protects macaques from vaginal simian-human immunodeficiency virus challenge Antimicrobial Agents and Chemotherapy 2016 60:693-698 DOI:10.1128/aac.01925-15 PMID:26552985 PMCID:PMC4704173
- Gallay, P. A., Chatterji, U., Bobardt, M. D., Long, Z., Zhang, S., Su, Z. Characterization of the anti-HCV activities of the new cyclophilin inhibitor STG-175 PLoS One 2016 11 DOI:10.1371/journal.pone.0152036 PMID:27104614 PMCID:PMC4841536
- Chatterji, U., Bobardt, M., Schaffer, L., Wood, M., Gallay, P. A. Cyclophilin inhibitors remodel the endoplasmic reticulum of HCV-infected cells in a unique pattern rendering cells impervious to a reinfection PLoS One 2016 11 DOI:10.1371/journal.pone.0159511 PMID:27442520 PMCID:PMC4956074
- Phillips, S., Chokshi, S., Chatterji, U., Riva, A., Bobardt, M., Williams, R., Gallay, P., Naoumov, N. V. Alisporivir inhibition of hepatocyte cyclophilins reduces HBV replication and hepatitis B surface antigen production Gastroenterology 2015 148:403-414 DOI:10.1053/j.gastro.2014.10.004 PMID:25305505
- Hansson, M. J., Moss, S. J., Bobardt, M., Chatterji, U., Coates, N., Garcia-Rivera, J. A., Elmer, E., Kendrew, S., Leyssen, P., Neyts, J., Nur-E-Alam, M., Warneck, T., et al. Bioengineering and semisynthesis of an optimized cyclophilin inhibitor for treatment of chronic viral infection Chemistry & Biology 2015 22:285-292 DOI:10.1016/j.chembiol.2014.10.023 PMID:25619934 PMCID:PMC4336584
- Chatterji, U., Bobardt, M., Tai, A., Wood, M., Gallay, P. A. Cyclophilin and NS5A inhibitors, but not other anti-hepatitis C virus (HCV) agents, preclude HCV-mediated formation of double-membrane-vesicle viral factories Antimicrobial Agents and Chemotherapy 2015 59:2496-2507 DOI:10.1128/aac.04958-14 PMID:25666154
- Gallay, P. A., Bobardt, M. D., Chatterji, U., Trepanier, D. J., Ure, D., Ordonez, C., Foster, R. The novel cyclophilin inhibitor CPI-431-32 concurrently blocks HCV and HIV-1 infections via a similar mechanism of action PLoS One 2015 10:e0134707 DOI:10.1371/journal.pone.0134707 PMID:26263487 PMCID:PMC4532424
- Hopkins, S., Gallay, P. A. The role of immunophilins in viral infection Biochimica et Biophysica Acta-General Subjects 2015 1850:2103-2110 DOI:10.1016/j.bbagen.2014.11.011 PMID:25445708 PMCID:PMC4491039
- Chamoun-Emanuelli, A. M., Bobardt, M., Moncla, B., Mankowski, M. K., Ptak, R. G., Gallay, P., Chen, Z. Evaluation of PD 404,182 as an anti-HIV and anti-herpes simplex virus microbicide Antimicrobial Agents and Chemotherapy 2014 58:687-697 DOI:10.1128/aac.02000-13 PMID:24217696 PMCID:PMC3910842
- Gawlik, K., Gallay, P. A. HCV core protein and virus assembly: what we know without structures Immunologic Research 2014 60:1-10 DOI:10.1007/s12026-014-8494-3 PMID:24557493
- Gawlik, K., Baugh, J., Chatterji, U., Lim, P. J., Bobardt, M. D., Gallay, P. A. HCV core residues critical for infectivity are also involved in core-NS5A complex formation PLoS One 2014 9:e88866 DOI:10.1371/journal.pone.0088866 PMID:24533158 PMCID:PMC3923060
- Lim, P. J., Gallay, P. A. Hepatitis C NS5A protein: two drug targets within the same protein with different mechanisms of resistance Current Opinion in Virology 2014 8:30-37 DOI:10.1016/j.coviro.2014.04.012 PMID:24879295 PMCID:PMC4195798
- Chatterji, U., Garcia-Rivera, J. A., Baugh, J., Gawlik, K., Wong, K. A., Zhong, W., Brass, C. A., Naoumov, N. V., Gallay, P. A. The combination of alisporivir plus an NS5A inhibitor provides additive to synergistic anti-hepatitis C virus activity without detectable cross-resistance Antimicrobial Agents and Chemotherapy 2014 58:3327-3334 DOI:10.1128/aac.00016-14 PMID:24687498 PMCID:PMC4068438
- Gallay, P. A., Ptak, R. G., Bobardt, M. D., Dumont, J. M., Vuagniaux, G., Rosenwirth, B. Correlation of naturally occurring HIV-1 resistance to DEB025 with capsid amino acid polymorphisms Viruses-Basel 2013 5:981-997 DOI:10.3390/v5030981 PMID:23524389 PMCID:PMC3705307
- Lin, K., Gallay, P. Curing a viral infection by targeting the host: The example of cyclophilin inhibitors Antiviral Research 2013 99:68-77 DOI:10.1016/j.antiviral.2013.03.020 PMID:23578729 PMCID:PMC4332838
- Bobardt, M., Hopkins, S., Baugh, J., Chatterji, U., Hernandez, F., Hiscott, J., Sluder, A., Lin, K., Gallay, P. A. HCV NS5A and IRF9 compete for CypA binding Journal of Hepatology 2013 58:16-23 DOI:10.1016/j.jhep.2012.08.007 PMID:22902549 PMCID:PMC3527675
- Baugh, J. M., Garcia-Rivera, J. A., Gallay, P. A. Host-targeting agents in the treatment of hepatitis C: A beginning and an end? Antiviral Research 2013 100:555-561 DOI:10.1016/j.antiviral.2013.09.020 PMID:24091203 PMCID:PMC3971122
- Gallay, P. A., Lin, K. Profile of alisporivir and its potential in the treatment of hepatitis C Drug Design Development and Therapy 2013 7:105-115 DOI:10.2147/dddt.s30946 PMID:23440335 PMCID:PMC3578503
- Selvarajah, S., Chatterji, U., Kuhn, R., Kinney, R., Vasudevan, S. G., Gallay, P. Development and evaluation of an enzyme-linked immunosorbent assay for dengue capsid The Open Virology Journal 2012 6:29-37 DOI:10.2174/1874357901206010029 PMID:22496714 PMCID:PMC3322434
- Lim, P. J., Chatterji, U., Cordek, D., Sharma, S. D., Garcia-Rivera, J. A., Cameron, C. E., Lin, K., Targett-Adams, P., Gallay, P. A. Correlation between NS5A dimerization and hepatitis C virus replication Journal of Biological Chemistry 2012 287:30861-30873 DOI:10.1074/jbc.M112.376822 PMID:22801423 PMCID:PMC3436329
- Gallay, P. A. Cyclophilin inhibitors: A novel class of promising host-targeting anti-HCV agents Immunologic Research 2012 52:200-210 DOI:10.1007/s12026-011-8263-5 PMID:22169996
- Hopkins, S., Gallay, P. Cyclophilin inhibitors: An emerging class of therapeutics for the treatment of chronic hepatitis C infection Viruses-Basel 2012 4:2558-2577 DOI:10.3390/v4112558 PMID:23202494 PMCID:PMC3509662
- Baugh, J., Gallay, P. Cyclophilin involvement in the replication of hepatitis C virus and other viruses Biological Chemistry 2012 393:579-587 DOI:10.1515/hsz-2012-0151 PMID:22944661
- Garcia-Rivera, J. A., Bobardt, M., Chatterji, U., Hopkins, S., Gregory, M. A., Wilkinson, B., Lin, K., Gallay, P. A. Multiple mutations in hepatitis C virus NS5A domain II are required to confer a significant level of resistance to alisporivir Antimicrobial Agents and Chemotherapy 2012 56:5113-5121 DOI:10.1128/aac.00919-12 PMID:22802259 PMCID:PMC3457393
- Chamoun, A. M., Chockalingam, K., Bobardt, M., Simeon, R., Chang, J. H., Gallay, P., Chen, Z. L. PD 404,182 is a virocidal small molecule that disrupts hepatitis C virus and human immunodeficiency virus Antimicrobial Agents and Chemotherapy 2012 56:672-681 DOI:10.1128/aac.05722-11 PMID:22083468 PMCID:PMC3264232
- Moss, S. J., Bobardt, M., Leyssen, P., Coates, N., Chatterji, U., Xie, D. J., Foster, T., Liu, J. L., Nur-e-Alam, M., Suthar, D., Chen, Y. S., Warneck, T., et al. Sangamides, a new class of cyclophilin-inhibiting host-targeted antivirals for treatment of hcv infection MedChemComm 2012 3:938-943 DOI:10.1039/c1md00227a
- Maskiewicz, R., Bobardt, M., Chatterji, U., Gunaseelan, S., Dezzutti, C. S., Penin, F., Gallay, P. A. Sublimable C5A delivery provides sustained and prolonged anti-hiv microbicidal activities Antimicrobial Agents and Chemotherapy 2012 56:3336-3343 DOI:10.1128/aac.00186-12 PMID:22430971 PMCID:PMC3370808
- Gunaseelan, S., Gallay, P. A., Bobardt, M. D., Dezzutti, C. S., Esch, T., Maskiewicz, R. Sustained local delivery of structurally diverse HIV-1 microbicides released from sublimation enthalpy controlled matrices Pharmaceutical Research 2012 29:3156-3168 DOI:10.1007/s11095-012-0811-8 PMID:22736232 PMCID:PMC3473190
- Hopkins, S., Bobardt, M., Chatterji, U., Garcia-Rivera, J. A., Lim, P., Gallay, P. A. The cyclophilin inhibitor SCY-635 disrupts hepatitis C virus NS5A-cyclophilin A complexes Antimicrobial Agents and Chemotherapy 2012 56:3888-3897 DOI:10.1128/aac.00693-12 PMID:22585215 PMCID:PMC3393457
- Hopkins, S., DiMassimo, B., Rusnak, P., Heuman, D., Lalezari, J., Sluder, A., Scorneaux, B., Mosier, S., Kowalczyk, P., Ribeill, Y., Baugh, J., Gallay, P. The cyclophilin inhibitor SCY-635 suppresses viral replication and induces endogenous interferons in patients with chronic HCV genotype 1 infection Journal of Hepatology 2012 57:47-54 DOI:10.1016/j.jhep.2012.02.024 PMID:22425702
- Foster, T. L., Gallay, P., Stonehouse, N. J., Harris, M. Cyclophilin A interacts with domain II of hepatitis C virus NS5A and stimulates RNA binding in an isomerase-dependent manner Journal of Virology 2011 85:7460-7464 DOI:10.1128/jvi.00393-11 PMID:21593166 PMCID:PMC3126559
- de Witte, L., Bobardt, M. D., Chatterji, U., van Loenen, F. B., Verjans, Gmgm, Geijtenbeek, T. B. H., Gallay, P. A. HSV neutralization by the microbicidal candidate C5A PLoS One 2011 6:e18917 DOI:10.1371/journal.pone.0018917 PMID:21573158 PMCID:PMC3089603
- Denton, P. W., Othieno, F., Martinez-Torres, F., Zou, W., Krisko, J. F., Fleming, E., Zein, S., Powell, D. A., Wahl, A., Kwak, Y. T., Welch, B. D., Kay, M. S., et al. One percent tenofovir applied topically to humanized BLT mice and used according to the CAPRISA 004 experimental design demonstrates partial protection from vaginal HIV infection, validating the blt model for evaluation of new microbicide candidates Journal of Virology 2011 85:7582-7593 DOI:10.1128/jvi.00537-11 PMID:21593172 PMCID:PMC3147928
- Gregory, M. A., Bobardt, M., Obeid, S., Chatterji, U., Coates, N. J., Foster, T., Gallay, P., Leyssen, P., Moss, S. J., Neyts, J., Nur-e-Alam, M., Paeshuyse, J., et al. Preclinical characterization of naturally occurring polyketide cyclophilin inhibitors from the sanglifehrin family Antimicrobial Agents and Chemotherapy 2011 55:1975-1981 DOI:10.1128/aac.01627-10 PMID:21383094 PMCID:PMC3088210
- Chatterji, U., Bobardt, M. D., Lim, P., Gallay, P. A. Cyclophilin A-independent recruitment of NS5A and NS5B into hepatitis C virus replication complexes Journal of General Virology 2010 91:1189-1193 DOI:10.1099/vir.0.018531-0 PMID:20107018 PMCID:PMC2888154
- Fischer, G., Gallay, P., Hopkins, S. Cyclophilin inhibitors for the treatment of HCV infection Current Opinion in Investigational Drugs 2010 11:911-918 PMID:20721833
- Coelmont, L., Hanoulle, X., Chatterji, U., Berger, C., Snoeck, J., Bobardt, M., Lim, P., Vliegen, I., Paeshuyse, J., Vuagniaux, G., Vandamme, A. M., Bartenschlager, R., et al. DEB025 (Alisporivir) inhibits hepatitis C virus replication by preventing a cyclophilin A induced cis-trans isomerisation in domain II of NS5A PLoS One 2010 5:e13687 DOI:10.1371/journal.pone.0013687 PMID:21060866 PMCID:PMC2965138
- Chatterji, U., Lim, P., Bobardt, M. D., Wieland, S., Cordek, D. G., Vuagniaux, G., Chisari, F., Cameron, C. E., Targett-Adams, P., Parkinson, T., Gallay, P. A. HCV resistance to cyclosporin A does not correlate with a resistance of the NS5A-cyclophilin A interaction to cyclophilin inhibitors Journal of Hepatology 2010 53:50-56 DOI:10.1016/j.jhep.2010.01.041 PMID:20451281 PMCID:PMC2884070
- Bobardt, M. D., Chatterji, U., Schaffer, L., de Witte, L., Gallay, P. A. Syndecan-fc hybrid molecule as a potent in vitro microbicidal anti-hiv-1 agent Antimicrobial Agents and Chemotherapy 2010 54:2753-2766 DOI:10.1128/aac.01606-09 PMID:20439611 PMCID:PMC2897270
- Waller, H., Chatterji, U., Gallay, P., Parkinson, T., Targett-Adams, P. The use of AlphaLISA technology to detect interaction between hepatitis C virus-encoded NS5A and cyclophilin A Journal of Virological Methods 2010 165:202-210 DOI:10.1016/j.jviromet.2010.01.020 PMID:20132841
- Gallay, P. A. Cyclophilin inhibitors Clinics in Liver Disease 2009 13:403-417 DOI:10.1016/j.cld.2009.05.002 PMID:19628157
- Chatterji, U., Bobardt, M., Selvarajah, S., Yang, F., Tang, H. L., Sakamoto, N., Vuagniaux, G., Parkinson, T., Gallay, P. The isomerase active site of cyclophilin A is critical for hepatitis C virus replication Journal of Biological Chemistry 2009 284:16998-17005 DOI:10.1074/jbc.M109.007625 PMID:19380579 PMCID:PMC2719337
- Cheng, G., Montero, A., Gastaminza, P., Whitten-Bauer, C., Wieland, S. F., Isogawa, M., Fredericksen, B., Selvarajah, S., Gallay, P. A., Ghadiri, M. R., Chisari, F. V. A virocidal amphipathic α-helical peptide that inhibits hepatitis C virus infection in vitro Proceedings of the National Academy of Sciences of the United States of America 2008 105:3088-3093 DOI:10.1073/pnas.0712380105 PMID:18287023 PMCID:PMC2268589
- Bobardt, M. D., Cheng, G. F., de Witte, L., Selvarajah, S., Chatterji, U., Sanders-Beer, B. E., Geijtenbeek, T. B. H., Chisari, F. V., Gallay, P. A. Hepatitis C virus NS5A anchor peptide disrupts human immunodeficiency virus Proceedings of the National Academy of Sciences of the United States of America 2008 105:5525-5530 DOI:10.1073/pnas.0801388105 PMID:18378908 PMCID:PMC2291127
- Ptak, R. G., Gallay, P. A., Jochmans, D., Halestrap, A. P., Ruegg, U. T., Pallansch, L. A., Bobardt, M. D., de Bethune, M. P., Neyts, J., De Clercq, E., Dumont, J. M., Scalfaro, P., et al. Inhibition of human immunodeficiency virus type 1 replication in human cells by Debio-025, a novel cyclophilin binding agent Antimicrobial Agents and Chemotherapy 2008 52:1302-1317 DOI:10.1128/aac.01324-07 PMID:18212100 PMCID:PMC2292519
- de Jong, Mawp, de Witte, L., Oudhoff, M. J., Gringhuis, S. I., Gallay, P., Geijtenbeek, T. B. H. TNF-alpha and TLR agonists increase susceptibility to HIV-1 transmission by human langerhans cells ex vivo Journal of Clinical Investigation 2008 118:3440-3452 DOI:10.1172/jci34721 PMID:18776939 PMCID:PMC2528910
- Flisiak, R., Horban, A., Gallay, P., Bobardt, M., Selvarajah, S., Wiercinska-Drapalo, A., Siwak, E., Cielniak, I., Higersberger, J., Kierkus, J., Aeschlimann, C., Grosgurin, P., et al. The cyclophilin inhibitor Debio-025 shows potent anti-hepatitis C effect in patients coinfected with hepatitis C and human immunodeficiency virus Hepatology 2008 47:817-826 DOI:10.1002/hep.22131 PMID:18302285
- Bobardt, M. D., Chatterji, U., Selvarajah, S. A., Van der Schueren, B., David, G., Kahn, B., Gallay, P. A. Cell-free human immunodeficiency virus type 1 transcytosis through primary genital epithelial cells Journal of Virology 2007 81:395-405 DOI:10.1128/jvi.01303-06 PMID:17050597
- de Witte, L., Bobardt, M., Chatterji, U., Degeest, G., David, G., Geijtenbeek, T. B. H., Gallay, P. Syndecan-3 is a dendritic cell-specific attachment receptor for HIV-1 Proceedings of the National Academy of Sciences of the United States of America 2007 104:19464-19469 DOI:10.1073/pnas.0703747104 PMID:18040049 PMCID:PMC2148312
- Binley, J. M., Ngo-Abdalla, S., Moore, P., Bobardt, M., Chatterji, U., Gallay, P., Burton, D. R., Wilson, I. A., Elder, J. H., de Parseval, A. Inhibition of HIV ENV binding to cellular receptors by monoclonal antibody 2G12 as probed by Fc-tagged gp120 Retrovirology 2006 3:39 DOI:10.1186/1742-4690-3-39 PMID:16817962 PMCID:PMC1543650
- Saphire, A. C. S., Gallay, P. A., Bark, S. J. Proteomic analysis of human immunodeficency virus using liquid chromatography/tandem mass spectrometry effectively distinguishes specific incorporated host proteins Journal of Proteome Research 2006 5:530-538 DOI:10.1021/pr050276b PMID:16512667
- Chatterji, U., Bobardt, M. D., Gaskill, P., Sheeter, D., Fox, H., Gallay, P. A. Trim5α accelerates degradation of cytosolic capsid associated with productive HIV-1 entry Journal of Biological Chemistry 2006 281:37025-37033 DOI:10.1074/jbc.M606066200 PMID:17028189
- de Parseval, A., Bobardt, M. D., Chatterji, A., Chatterji, U., Elder, J. H., David, G., Zolla-Pazner, S., Farzan, M., Lee, T. H., Gallay, P. A. A highly conserved arginine in gp120 governs HIV-1 binding to both syndecans and CCR5 via sulfated motifs Journal of Biological Chemistry 2005 280:39493-39504 DOI:10.1074/jbc.M504233200 PMID:16157597
- Chatterji, U., Bobardt, M. D., Stanfield, R., Ptak, R. G., Pallansch, L. A., Ward, P. A., Jones, M. J., Stoddart, C. A., Scalfaro, P., Dumont, J. M., Besseghir, K., Rosenwirth, B., et al. Naturally occurring capsid substitutions render HIV-1 cyclophilin A independent in human cells and TRIM-cyclophilin-resistant in Owl monkey cells Journal of Biological Chemistry 2005 280:40293-40300 DOI:10.1074/jbc.M506314200 PMID:16199531
- Barry, S. M., Melar, M., Gallay, P., Hope, T. J. Review of the twelfth west coast retrovirus meeting Retrovirology 2005 2:72 DOI:10.1186/1742-4690-2-72 PMID:16293194 PMCID:PMC1315336
- Bobardt, M. D., Salmon, P., Wang, L. C., Esko, J. D., Gabuzda, D., Fiala, M., Trono, D., Van der Schueren, B., David, G., Gallay, P. A. Contribution of proteoglycans to human immunodeficiency virus type 1 brain invasion Journal of Virology 2004 78:6567-6584 DOI:10.1128/jvi.78.12.6567-6584.2004 PMID:15163749
- Galigniana, M. D., Morishima, Y., Gallay, P. A., Pratt, W. B. Cyclophilin-A is bound through its peptidylprolyl isomerase domain to the cytoplasmic dynein motor protein complex Journal of Biological Chemistry 2004 279:55754-55759 DOI:10.1074/jbc.M406259200 PMID:15496417
- Bobardt, M. D., Armand-Ugon, M., Clotet, I., Zhang, Z., David, G., Este, J. A., Gallay, P. A. Effect of polyanion-resistance on HIV-1 infection Virology 2004 325:389-398 DOI:10.1016/j.virol.2004.05.011 PMID:15246277
- Gallay, P. Syndecans and HIV-1 pathogenesis Microbes and Infection 2004 6:617-622 DOI:10.1016/j.micinf.2004.02.004 PMID:15158197
- Bobardt, M. D., Saphire, A. C. S., Hung, H. C., Yu, X. C., Van der Schueren, B., Zhang, Z., David, G., Gallay, P. A. Syndecan captures, protects, and transmits HIV to T lymphocytes Immunity 2003 18:27-39 DOI:10.1016/s1074-7613(02)00504-6 PMID:12530973
- Yurchenko, V., Zybarth, G., O'Connor, M., Dai, W. W., Franchin, G., Hao, T., Guo, H. M., Hung, H. C., Toole, B., Gallay, P., Sherry, B., Bukrinsky, M. Active site residues of cyclophilin A are crucial for its signaling activity via CD147 Journal of Biological Chemistry 2002 277:22959-22965 DOI:10.1074/jbc.M201593200 PMID:11943775
- Saphire, A. C. S., Bobardt, M. D., Gallay, P. A. Cyclophilin A plays distinct roles in human immunodeficiency virus type 1 entry and postentry events, as revealed by spinoculation Journal of Virology 2002 76:4671-4677 DOI:10.1128/jvi.76.9.4671-4677.2002 PMID:11932436
- Saphire, A. C. S., Bobardt, M. D., Gallay, P. A. Trans-complementation rescue of cyclophilin A-deficient viruses reveals that the requirement for cyclophilin A in human immunodeficiency virus type 1 replication is independent of its isomerase activity Journal of Virology 2002 76:2255-2262 DOI:10.1128/jvi.76.5.2255-2262.2002 PMID:11836403
- Saphire, A. C. S., Bobardt, M. D., Zhang, Z., David, G., Gallay, P. A. Syndecans serve as attachment receptors for human immunodeficiency virus type 1 on macrophages Journal of Virology 2001 75:9187-9200 DOI:10.1128/jvi.75.19.9187-9200.2001 PMID:11533182
- Saphire, A. C. S., Bobardt, M. D., Gallay, P. A. Human immunodeficiency virus type 1 hijacks host cyclophilin A for its attachment to target cells Immunologic Research 2000 21:211-217 DOI:10.1385/ir:21:2-3:211 PMID:10852119
- Saphire, A. C. S., Bobardt, M. D., Gallay, P. A. Host cyclophilin A mediates HIV-1 attachment to target cells via heparans EMBO Journal 1999 18:6771-6785 DOI:10.1093/emboj/18.23.6771 PMID:10581250 PMCID:PMC1171739
- Gallay, P., Hope, T., Chin, D., Trono, D. HIV-1 infection of nondividing cells through the recognition of integrase by the importin/karyopherin pathway Proceedings of the National Academy of Sciences of the United States of America 1997 94:9825-9830 DOI:10.1073/pnas.94.18.9825 PMID:9275210
- Camaur, D., Gallay, P., Swingler, S., Trono, D. Human immunodeficiency virus matrix tyrosine phosphorylation: Characterization of the kinase and its substrate requirements Journal of Virology 1997 71:6834-6841 PMID:9261408 PMCID:PMC191964
- Swingler, S., Gallay, P., Camaur, D., Song, J. P., Abo, A., Trono, D. The nef protein of human immunodeficiency virus type 1 enhances serine phosphorylation of the viral matrix Journal of Virology 1997 71:4372-4377 PMID:9151826 PMCID:PMC191654
- Naldini, L., Blomer, U., Gallay, P., Ory, D., Mulligan, R., Gage, F. H., Verma, I. M., Trono, D. In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector Science 1996 272:263-267 DOI:10.1126/science.272.5259.263 PMID:8602510
- Gallay, P., Stitt, V., Mundy, C., Oettinger, M., Trono, D. Role of the karyopherin pathway in human immunodeficiency virus type 1 nuclear import Journal of Virology 1996 70:1027-1032 PMID:8551560 PMCID:PMC189908
- Horadagoda, N. U., Eckersall, P. D., Andrew, L., Gallay, P., Heumann, D., Gibbs, H. A. Characterisation of bovine lipopolysaccharide binding protein and the in vivo acute phase response to Pasteurella haemolytica Type A Veterinary Immunology and Immunopathology 1995 49:61-74 DOI:10.1016/0165-2427(95)05458-i PMID:8588345
- Heumann, D., Gallay, P., Le Roy, D., Glauser, M. P. Contribution of lipopolysaccharide binding protein (LBP) in endotoxemic shock in mice Progress in Clinical and Biological Research 1995 392:465-471 PMID:8524953
- Heumann, D., Bas, S., Gallay, P., Leroy, D., Barras, C., Mensi, N., Glauser, M. P., Vischer, T. Lipopolysaccharide binding protein as a marker of inflammation in synovial fluid of patients with arthritis: correlation with interleukin 6 and C-reactive protein Journal of Rheumatology 1995 22:1224-1229 PMID:7562749
- Gallay, P., Swingler, S., Song, J. P., Bushman, F., Trono, D. HIV nuclear import is governed by the phosphotyrosine-mediated binding of matrix to the core domain of integrase Cell 1995 83:569-576 DOI:10.1016/0092-8674(95)90097-7 PMID:7585960
- Gallay, P., Swingler, S., Aiken, C., Trono, D. HIV-1 infection of nondividing cells - C-terminal tyrosine phosphorylation of the viral matrix protein is a key regulator Cell 1995 80:379-388 DOI:10.1016/0092-8674(95)90488-3 PMID:7859280
- Schook, L. B., Albrecht, H., Gallay, P., Jongeneel, C. V. Cytokine regulation of TNF-alpha mRNA and protein production by unprimed macrophages from C57Bl/6 and NZW mice Journal of Leukocyte Biology 1994 56:514-520 PMID:7930949
- Car, B. D., Eng, V. M., Schnyder, B., Ozmen, L., Huang, S., Gallay, P., Heumann, D., Aguet, M., Ryffel, B. Interferon gamma receptor deficient mice are resistant to endotoxic shock Journal of Experimental Medicine 1994 179:1437-1444 DOI:10.1084/jem.179.5.1437 PMID:8163930 PMCID:PMC2191498
- Gallay, P., Heumann, D., Leroy, D., Barras, C., Glauser, M. P. Mode of action of anti-lipopolysaccharide-binding protein antibodies for prevention of endotoxemic shock in mice Proceedings of the National Academy of Sciences of the United States of America 1994 91:7922-7926 DOI:10.1073/pnas.91.17.7922 PMID:7520172 PMCID:PMC44516
- Heumann, D., Gallay, P., Leroy, D., Landmann, R., Glauser, M. P. Radioimmunoassay versus flow cytometric assay to quantify LPS-binding protein (LBP) concentrations in human plasma Journal of Immunological Methods 1994 171:169-176 DOI:10.1016/0022-1759(94)90037-x PMID:7515085
- Corradin, S. B., Heumann, D., Gallay, P., Smith, J., Mauel, J., Glauser, M. P. Bactericidal permeability-increasing protein inhibits induction of macrophage nitric-oxide production by lipopolysaccharide Journal of Infectious Diseases 1994 169:105-111 PMID:8277172
- Gallay, P., Barras, C., Tobias, P. S., Calandra, T., Glauser, M. P., Heumann, D. Lipopolysaccharide (LPS)-binding protein in human serum determines the tumor-necrosis-factor response of monocytes to LPS Journal of Infectious Diseases 1994 170:1319-1322 PMID:7963737
- Gallay, P., Heumann, D., Leroy, D., Barras, C., Glauser, M. P. Lipopolysaccharide-binding protein as a major plasma protein responsible for endotoxemic shock Proceedings of the National Academy of Sciences of the United States of America 1993 90:9935-9938 DOI:10.1073/pnas.90.21.9935 PMID:7694297 PMCID:PMC47687
- Gallay, P., Jongeneel, C. V., Barras, C., Burnier, M., Baumgartner, J. D., Glauser, M. P., Heumann, D. Short time exposure to lipopolysaccharide is sufficient to activate human monocytes Journal of Immunology 1993 150:5086-5093 PMID:7684419
- Heumann, D., Gallay, P., Betzcorradin, S., Barras, C., Baumgartner, J. D., Glauser, M. P. Competition between bactericidal permeability-increasing protein and lipopolysaccharide-binding protein for lipopolysaccharide binding to monocytes Journal of Infectious Diseases 1993 167:1351-1357 PMID:8501324
- Gauthier, T., Hamou, M. F., Monod, L., Gallay, P., Carrel, S., Detribolet, N. Expression and release of interleukin-1 by human glioblastoma cells in vitro and in vivo Acta Neurochirurgica 1993 121:199-205 DOI:10.1007/bf01809276 PMID:8512018
- Gallay, P., Carrel, S., Glauser, M. P., Barras, C., Ulevitch, R. J., Tobias, P. S., Baumgartner, J. D., Heumann, D. Purification and characterization of murine lipopolysaccharide-binding protein Infection and Immunity 1993 61:378-383 PMID:7678583 PMCID:PMC302740
- Heumann, D., Gallay, P., Barras, C., Zaech, P., Ulevitch, R. J., Tobias, P. S., Glauser, M. P., Baumgartner, J. D. Control of lipopolysaccharide (lps) binding and lps-induced tumor-necrosis-factor secretion in human peripheral-blood monocytes Journal of Immunology 1992 148:3505-3512 PMID:1375247
- Corradin, S. B., Mauel, J., Gallay, P., Heumann, D., Ulevitch, R. J., Tobias, P. S. Enhancement of murine macrophage binding of and response to bacterial lipopolysaccharide (LPS) by LPS-binding protein Journal of Leukocyte Biology 1992 52:363-368 PMID:1402386
- Gallay, P., Mach, J. P., Carrel, S. Characterization and detection of naturally occurring antibodies against IL-1 alpha and IL-1 beta in normal human plasma Eur Cytokine Netw 1991 2:329-38
- Carrel, S., Salvi, S., Gallay, P., Rapin, C., Sekaly, R. P. Positive signal transduction via surface cd4 molecules does not need coexpression of the cd3/tcr complex Research in Immunology 1991 142:97-108 DOI:10.1016/0923-2494(91)90017-d PMID:1678202
- Carrel, S., Salvi, S., Isler, P., Rapin, C., Hayoz, D., Gallay, P., Giuffre, L. Gp33-38, an early human T-cell activation antigen Journal of Immunology 1990 144:2053-2062 PMID:2138192
-
patent
- Chisari, F. V., Gallay, P., inventors; Chisari, assignee. Amphipathic antiviral peptides for prevention of infection by measles or respiratory syncytial virus World patent WO2008086042A2 (2008).